Recombinant Mouse Endoglin/CD105 protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg1292

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Endoglin/CD105 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <1.0 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse Endoglin/CD105 protein Glu27-Lys580 (Accession# Q63961) with a His tag at the C-terminus.
• GeneID: 13805
• Accession: Q63961
• PredictedSize: 60.9 kDa
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Endoglin (ENG, CD105) is a homodimeric cell membrane glycoprotein of 180 kDa, composed of disulphide-linked subunits of 90-95 kDa. Endoglin is a proliferation-associated and hypoxia-inducible protein mainly expressed on vascular endothelial cells. It acts as an accessory receptor for transforming growth factor beta (TFG-β) and is involved in vascular development and remodelling. The important role of Endoglin in angiogenesis and in tumor progression makes it an ideal target for antiangiogenic therapy and a good marker for tumor prognosis.

References:

1. Cheifetz, S et al. The Journal of biological chemistry vol. 267,27 (1992): 19027-30.
2. Fonsatti, Ester et al. Oncogene vol. 22,42 (2003): 6557-63.
3. Nassiri, Farshad et al. Anticancer research vol. 31,6 (2011): 2283-90.
4. Duff, Sarah E et al. FASEB journal vol. 17,9 (2003): 984-92.